Press release
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
New data on NovaSeq X Plus and workflow insights on Illumina Complete Long Reads unveiled at AGBT HOLLYWOOD, Fla., Feb. 8, 2023 /PRNewswire/ -- Illumina Inc.
About this update from Illumina, Inc.
[{"type":"text","content":"New data on NovaSeq X Plus and workflow insights on Illumina Complete Long Reads unveiled at AGBT\nHOLLYWOOD, Fla., Feb. 8, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute. Alex Aravanis, PhD, chief technology officer of Illumina, made the announcement today in a presentation at the Advances in Genome Biology and Technology (AGBT) conference in Hollywood, Florida. Aravanis also announced much anticipated updates on Illumina's innovation roadmap including Illumina Complete Long Reads, the company's long-read sequencing technology, and its XLEAP SBS chemistry. Both the NovaSeq X Series and Illumina Complete Long Reads were announced in September 2022.\n\nWorld's first NovaSeq X delivery\nThe NovaSeq X Series is Illumina's most powerful sequencing system, delivering an unprecedented combination of high throughput and accuracy, and featuring streamlined informatics, breakthrough sustainability advancements, and cost-effective sequencing economics. Aravanis announced today that the Broad Institute has received the world's first shipment.\n\"We are thrilled to see the NovaSeq X Plus beginning to ship to our customers after years in research and development, and now their biggest aspirations can be realized: enabling projects never previously thought possible,\" said Aravanis. \"We know our customers are eager to embark on more, deeper, and larger genomic research driven by operational ease and lower costs.\" \nAt AGBT, Niall Lennon, PhD, senior director of translational genomics at the Broad Institute of MIT and Harvard, presented alongside Aravanis, where he offered new data confirming that NovaSeq X Plus performance meets or exceeds that of the NovaSeq 6000.\n\"We are always excited to welcome new technologies that will allow the scientific community to do more, and larger, experiments,\" Lennon said. \"We anticipate that, once up and running, this platform will have a large impact on our ability to support groups wanting to access our walk-up sequencing service, our human whole genome product, and our blended genome/exome product.\" \nAs previously announced, Illumina is ramping up to ship 40-50 orders in this quarter and the company plans to ship more than 300 instrum...